CollPlant Expands Collaboration with STEMCELL Technologies

Collplant Holdings ( (CLGN) ) has shared an update.

On June 9, 2025, CollPlant Biotechnologies announced an expansion of its collaboration with STEMCELL Technologies, extending the use of its proprietary rhCollagen beyond research to include clinical development and commercial-scale manufacturing. This development underscores CollPlant’s commitment to providing safer, more effective, and sustainable solutions, positioning its plant-derived rhCollagen as a viable alternative to animal-sourced materials, aligning with industry priorities around safety, consistency, and ethical sourcing.

The most recent analyst rating on (CLGN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.

Spark’s Take on CLGN Stock

According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.

Collplant Holdings’ overall stock score reflects significant financial challenges, including declining revenue and cash flow issues, which are the primary concerns. Technical analysis provides some cautious optimism, but the negative valuation metrics suggest overvaluation. Despite promising product developments, financial instability remains a critical risk factor.

To see Spark’s full report on CLGN stock, click here.

More about Collplant Holdings

CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen). The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, addressing diverse fields such as tissue repair, aesthetics, and organ manufacturing.

Average Trading Volume: 76,260

Technical Sentiment Signal: Sell

Current Market Cap: $24.55M

See more insights into CLGN stock on TipRanks’ Stock Analysis page.